Dr Suzanne Saffie-Siebert shares Bio-Courier Tech to help treat and prevent Coronavirus

By Deanna Utroske contact

- Last updated on GMT

© Getty Images \ (peterschreiber.media)
© Getty Images \ (peterschreiber.media)

Related tags: coronavirus, Science, delivery mechanism, ingredient technology

The indie beauty brand founder and long-time drug delivery specialist has, just this week, made her company’s silicon-based hybrid ingredient delivery technologies available to researchers working to develop antivirals and Coronavirus treatments.

As many cosmetics and personal care industry suppliers and manufacturers know, there is a fair amount of cross-over and shared technology between the medical business and the beauty business.

Dr Suzanne Saffie-Siebert, Chairwoman and CEO of SiSaf Ltd (a commercial stage drug development company), saw an opportunity in skin care for the same bio-courier technology that she and her team use in the pharmaceutical space.

And in 2017, she launched the Good Science Beauty brand. As Saffie-Siebert explains in her Indie Beauty Profile“Good Science Beauty is incubated by…SiSaf Ltd, a global research and bio-pharmaceutical company that develops bio-courier technologies for healthcare, crop care, and animal health. Good Science Beauty is a wholly owned subsidiary of SiSaf and has exclusive rights over our patented technology, Good Silicon+, which my team and I spent almost ten years developing.”

That indie beauty brand is known for its line of skin care products spanning masks, creams, exfoliants, and more; as well as for its crisp, brightly colored secondary packaging, reminiscent of the periodic table of elements.

SiSaf Ltd shares proprietary technology with COVID-19 treatment and vaccine researchers

“I’m keen for SiSaf to fulfil its public health obligation in addressing the coronavirus pandemic in as many ways as possible,”​ Saffie-Siebert says in a news item posted this week on sisaf.com​.

Her company, she explains, “is uniquely positioned to support groups and help accelerate their programs, not only nucleic acid-based vaccine developers, but also groups exploring the use of antivirals and CD8 peptides for treatment.”

“Time is of the essence,” ​says Saffie-Siebert; “so I urge relevant health organizations and research groups to contact us. Then we can rapidly assess whether our technology can help and make our resources available on a not-for-profit basis.”

As she sees it, “the more approaches we explore, the better our likelihood of success to check the coronavirus challenge and prevent or manage future pandemics.”

The SiSal Ltd news item directs interested researchers to email vasb@fvfns.pbz​ or to visit www.sisaf.com​ to learn more.

---

DeannaUtroske-smallphoto

Deanna Utroske is a leading voice in the cosmetics and personal care industry as well as in the indie beauty movement. As Editor of CosmeticsDesign.com, she writes daily news about the business of beauty in the Americas region and regularly produces video interviews with cosmetics, fragrance, personal care, and packaging experts as well as with indie brand founders. Learn more about how the beauty industry is coming together during the COVID-19 crisis here.

Related news

Follow us

Products

View more

Webinars